This article has an accompanying continuing medical education activity, also eligible for
MOC credit, on page e20. Learning Objective: Upon completion of this CME activity …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Therapeutic drug monitoring (TDM), which involves measurement of drug or active
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Abstract Background and Aims Accelerated infliximab (IFX) induction is often based on
clinical parameters as opposed to pharmacokinetics (PK). We aimed to investigate the …

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and
adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis …

Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to
insufficient growth and late pubertal development in cases of disease onset during …

Infliximab (IFX) is administered intravenously using weight-based dosing (5 mg/kg) in
inflammatory bowel disease (IBD) patients. Our hypothesis is that especially young children …

Anti–tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory
bowel disease (IBD). However, up to 30% of patients with IBD show no clinical benefit and …

Background Acute severe ulcerative colitis (ASUC), the most aggressive presentation of
ulcerative colitis (UC), occurs in 15% of adults and children with UC. First line therapy with …